3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
12
Carcinoma, Hepatocellular
8
Small Cell Lung Carcinoma
7
Cholangiocarcinoma
7
Neoplasms
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms by Site
3
Gallbladder Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Vaccinia
1
Unresectable Hepatocellular Carcinoma
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Specimen Handling
3
pembrolizumab
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Biopsy
2
talimogene laherparepvec
1
peposertib
1
liposomal doxorubicin
1
fludarabine
1
aldesleukin
1
X-Rays
1
Radiotherapy
1
Radiation
1
Nivolumab
1
Ipilimumab
1
Histamine H2 Antagonists
1
Famotidine
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
durvalumab
×
30 days
×
Clear all
No trials found.